Polymeric gels for intravaginal drug delivery

Journal of Controlled Release

Volumn 270, Issue , 2018, Pages 145-157

  Cook, Michael T ^a   Brown, Marc B ^a,b  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b MEDPHARM LTD   (United Kingdom)

Author keywords

Clinical trials; HIV PrEP; In vitro models; Mucoadhesion; Regulatory approval; Thermogelling materials

Indexed keywords

DRUG DOSAGE; FUNCTIONAL POLYMERS; GELS; MEDICAL APPLICATIONS; PRASEODYMIUM COMPOUNDS; TARGETED DRUG DELIVERY;

CLINICAL TRIAL; HIV PREP; IN-VITRO MODELS; MUCOADHESION; REGULATORY APPROVALS; THERMOGELLING;

CONTROLLED DRUG DELIVERY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HORMONE; NEW DRUG; POLYMER; PROBIOTIC AGENT; PROSTAGLANDIN; SPERMICIDAL AGENT;

ANATOMY; CLINICAL TRIAL; CONTRACEPTION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG PENETRATION; DRUG QUALITY; DRUG SAFETY; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; MUCOADHESION; NONHUMAN; PHYSIOLOGY; POLYMERIZATION; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX MUCUS; UTERINE CERVIX RIPENING; VAGINA; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA FLORA; VAGINA PH; VAGINAL TRICHOMONIASIS; VAGINITIS; ADMINISTRATION AND DOSAGE; ANIMAL; FEMALE; METABOLISM;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; DOSAGE FORMS; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; FEMALE; GELS; HUMANS; POLYMERS; VAGINA;

EID: 85037531730     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.12.004     Document Type: Review

References (145)

1. Woolfson, A.D., Malcolm, R.K., Gallagher, R., Drug delivery by the intravaginal route. Crit. Rev. Ther. Drug Carrier Syst. 17 (2000), 509–555.
2. Karl Malcolm, R., Fetherston, S.M., McCoy, C.F., Boyd, P., Major, I., Vaginal rings for delivery of HIV microbicides. Int. J. Womens. Health. 4 (2012), 595–605.
3. Malcolm, R.K., Edwards, K.L., Kiser, P., Romano, J., Smith, T.J., Advances in microbicide vaginal rings. Antivir. Res. 88 (2010), S30–9.
4. D'Cruz, O.J., Uckun, F.M., Vaginal microbicides and their delivery platforms. Expert Opin. Drug Deliv., 2014, 1–18.
5. Ensign, L.M., Cone, R., Hanes, J., Nanoparticle-based drug delivery to the vagina: a review. J. Control. Release 190 (2014), 500–514.
6. das Neves, J., Nunes, R., Machado, A., Sarmento, B., Polymer-based nanocarriers for vaginal drug delivery. Adv. Drug Deliv. Rev. 92 (2015), 53–70.
7. Caramella, C.M., Rossi, S., Ferrari, F., Bonferoni, M.C., Sandri, G., Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv. Drug Deliv. Rev. 92 (2015), 39–52.
8. Hussain, A., Ahsan, F., The vagina as a route for systemic drug delivery. J. Control. Release 103 (2005), 301–313.
9. Antimisiaris, S.G., Mourtas, S., Recent advances on anti-HIV vaginal delivery systems development. Adv. Drug Deliv. Rev. 92 (2015), 123–145.
10. Ghosh, M., Secreted mucosal antimicrobials in the female reproductive tract that are important to consider for HIV prevention. Am. J. Reprod. Immunol. 71 (2014), 575–588.
11. Sharif, K., Olufowobi, O., The Structure, Chemistry and Physics of Human Cervical Mucus. Jordan, J.A., Singer, A., (eds.) The Cervix, 2009, Blackwell Publishing Ltd, 157–168.
12. Patton, D.L., Thwin, S.S., Meier, A., Hooton, T.M., Stapleton, A.E., Eschenbach, D.A., Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am. J. Obstet. Gynecol. 183 (2000), 967–973.
13. Ildgruben, A.K., Sjöberg, I.M., Hammarström, M.L.K.C., Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet. Gynecol. 102 (2003), 571–582.
14. Anderson, D.J., Marathe, J., Pudney, J., The structure of the human vaginal stratum Corneum and its role in immune defense. Am. J. Reprod. Immunol. 71 (2014), 618–623.
15. Squier, C.A., Mantz, M.J., Schlievert, P.M., Davis, C.C., Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J. Pharm. Sci. 97 (2008), 9–21.
16. Barnhart, K.T., Izquierdo, A., Pretorius, E.S., Shera, D.M., Shabbout, M., Shaunik, A., Baseline dimensions of the human vagina. Hum. Reprod. 21 (2006), 1618–1622.
17. Pendergrass, P.B., Belovicz, M.W., Reeves, C.A., Surface area of the human vagina as measured from vinyl polysiloxane casts. Gynecol. Obstet. Investig. 55 (2003), 110–113.
18. Sassi, A.B., McCullough, K.D., Cost, M.R., Hillier, S.L., Rohan, L.C., Permeability of tritiated water through human cervical and vaginal tissue. J. Pharm. Sci. 93:4 (2004), 2009–2016.
19. van der Bijl, P., Thompson, I.O., Squier, C.A., Comparative permeability of human vaginal and buccal mucosa to water. Eur. J. Oral Sci. 105 (1997), 571–575.
20. Lesch, C.A., Squier, C.A., Cruchley, A., Williams, D.M., Speight, P., The permeability of human oral mucosa and skin to water. J. Dent. Res. 68 (1989), 1345–1349, 10.1177/00220345890680091101.
21. Owen, D.H., Katz, D.F., A vaginal fluid simulant. Contraception 59 (1999), 91–95.
22. Chrétien, F.C., Berthou, J., Crystallographic investigation of the dried exudate of the major vestibular (Bartholin's) glands in women. Eur. J. Obstet. Gynecol. Reprod. Biol., 135, 2007.
23. Silvina, M., Tomás, J., Nader-macías, M.E., Effect of a medium simulating vaginal fluid on the growth and expression of beneficial characteristics of potentially probiotic lactobacilli. Commun. Curr. Res. Ad Educ. Top. Trends Appl. Microbiol., 2007, 732–739.
24. Shaw, J.L.V., Smith, C.R., Diamandis, E.P., Proteomic analysis of human cervico-vaginal fluid. J. Proteome Res. 6 (2007), 2859–2865.
25. Stone, A., Gamble, C.J., The quantity of vaginal fluid. Am. J. Obstet. Gynecol. 78 (1959), 279–281.
26. Mitchell, C., Paul, K., Agnew, K., Gaussman, R., Coombs, R.W., Hitti, J., Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J. Clin. Microbiol. 49 (2011), 735–736.
27. Godley, M.J., Quantitation of vaginal discharge in healthy volunteers. Br. J. Obstet. Gynaecol. 92 (1985), 739–742.
28. Marques, M.R.C., Loebenberg, R., Almukainzi, M., Simulated biological fluids with possible application in dissolution testing. Dissolution Technol. 18 (2011), 15–28.
29. Boskey, E.R., Cone, R.A., Whaley, K.J., Moench, T.R., Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum. Reprod. 16 (2001), 1809–1813.
30. Ravel, J., Gajer, P., Abdo, Z., Schneider, G.M., Koenig, S.S.K., McCulle, S.L., Karlebach, S., Gorle, R., Russell, J., Tacket, C.O., Brotman, R.M., Davis, C.C., Ault, K., Peralta, L., Forney, L.J., Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. U. S. A. 108:Suppl (2011), 4680–4687.
31. Fox, C.A., Meldrum, S.J., Watson, B.W., Continuous measurement by radio-telemetry of vaginal pH during human coitus. J. Reprod. Fertil. 33 (1973), 69–75.
32. Olmsted, S.S., Padgett, J.L., Yudin, A.I., Whaley, K.J., Moench, T.R., Cone, R.A., Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 81 (2001), 1930–1937.
33. Carlstedt, I., Lindgren, H., Sheehan, J.K., Ulmsten, U., Wingerup, L., Isolation and characterization of human cervical-mucus glycoproteins. Biochem. J. 211 (1983), 13–22.
34. Peppas, N.A., Huang, Y., Nanoscale technology of mucoadhesive interactions. Adv. Drug Deliv. Rev. 56 (2004), 1675–1687.
35. Andersch-Björkman, Y., Thomsson, K.A., Holmén Larsson, J.M., Ekerhovd, E., Hansson, G.C., Large scale identification of proteins, mucins, and their O-glycosylation in the endocervical mucus during the menstrual cycle. Mol. Cell. Proteomics 6 (2007), 708–716.
36. Elstein, M., Functions and physical properties of mucus in the female genital tract. Br. Med. Bull. 34 (1978), 83–88.
37. Cook, M.T., Khutoryanskiy, V.V., Mucoadhesion and mucosa-mimetic materials—a mini-review. Int. J. Pharm. 495 (2015), 991–998.
38. Khutoryanskiy, V.V., Advances in mucoadhesion and mucoadhesive polymers. Macromol. Biosci. 11 (2011), 748–764.
39. Sosnik, A., Das Neves, J., Sarmento, B., Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog. Polym. Sci. 39 (2014), 2030–2075.
40. Smart, J.D., The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliv. Rev. 57 (2005), 1556–1568.
41. Albrecht, K., Bernkop-Schnürch, A., Thiomers: forms, functions and applications to nanomedicine. Nanomedicine 2 (2007), 41–50.
42. Iqbal, J., Shahnaz, G., Dünnhaupt, S., Müller, C., Hintzen, F., Bernkop-Schnürch, A., Preactivated thiomers as mucoadhesive polymers for drug delivery. Biomaterials 33 (2012), 1528–1535.
43. Cook, M.T., Schmidt, S.A., Lee, E., Samprasit, W., Opanasopit, P., Khutoryanskiy, V.V., Synthesis of mucoadhesive thiol-bearing microgels from 2-(acetylthio)ethylacrylate and 2-hydroxyethylmethacrylate: novel drug delivery systems for chemotherapeutic agents to the bladder. J. Mater. Chem. B 3 (2015), 6599–6604.
44. Jabbari, E., Wisniewski, N., Peppas, N.A., Evidence of mucoadhesion by chain interpenetration at a poly (acrylic acid)/mucin interface using ATR-FTIR spectroscopy. J. Control. Release 26 (1993), 99–108.
45. Reichman, O., Sobel, J., Desquamative inflammatory vaginitis, Bailliere's. Best Pract. Res. Clin. Obstet. Gynaecol. 28 (2014), 1042–1050.
46. Edwards, L., Dermatologic causes of vaginitis: a clinical review. Dermatol. Clin. 28 (2010), 727–735.
47. Schmitt, C., Sobel, J.D., Meriwether, C., Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet. Gynecol. 79 (2005), 1020–1023.
48. Fidel, P.L., Immunity to Candida. Oral Dis. 8:Suppl. 2 (2002), 69–75.
49. Schwebke, J.R., Burgess, D., Trichomoniasis. Clin. Microbiol. Rev. 17 (2004), 794–803.
50. Schwebke, J.R., Lensing, S.Y., Sobel, J., Intravaginal metronidazole/miconazole for the treatment of vaginal trichomoniasis. Sex. Transm. Dis. 40 (2013), 710–714.
51. Joint Formulary Committe, British National Formulary. 2014, BMJ Gr. Pharm. Press, 65.
52. Sanchez, S., Garcia, P.J., Thomas, K.K., Catlin, M., Holmes, K.K., Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am. J. Obstet. Gynecol. 191 (2004), 1898–1906.
53. Brache, V., Payán, L.J., Faundes, A., Current status of contraceptive vaginal rings. Contraception 87 (2013), 264–272.
54. Thurman, A.R., Clark, M.R., Hurlburt, J.A., Doncel, G.F., Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int. J. Womens. Health. 5 (2013), 695–708.
55. Garg, S., Tambwekar, K.R., Vermani, K., Garg, A., Kaul, C.L., Zaneveld, L.J.D., Compendium of pharmaceutical excipients for vaginal formulations. Pharm. Technol., 2001, 14–25.
56. Lete, I., Cuesta, M.C., Marín, J.M., Guerra, S., Vaginal health in contraceptive vaginal ring users - a review. Eur J Contracept Reprod Health Care 18 (2013), 234–241.
57. Ramirez, M.M., Labor induction: a review of current methods. Obstet. Gynecol. Clin. N. Am. 38 (2011), 215–225.
58. Tenore, J.L., Methods for cervical ripening and induction of labor. Am. Fam. Physician 67 (2003), 2123–2128.
59. Stewart, J.D., Rayburn, W.F., Farmer, K.C., Liles, E.M., Schipul, A.H., Stanley, J.R., Effectiveness of prostaglandin E2 intracervical gel (Prepidil), with immediate oxytocin, versus vaginal insert (Cervidil) for induction of labor. Am. J. Obstet. Gynecol. 179 (1998), 1175–1180.
60. Ferguson, L.M., Rohan, L.C., The importance of the vaginal delivery route for antiretrovirals in HIV prevention. Ther. Deliv. 2 (2011), 1535–1550.
61. Shannon, K., Csete, J., Violence, condom negotiation, and HIV/STI risk among sex workers. JAMA 304 (2010), 573–574.
62. Baeten, J.M., Palanee-Phillips, T., Brown, E.R., Schwartz, K., Soto-Torres, L.E., Govender, V., Mgodi, N.M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., Siva, S., Bekker, L.-G., Jeenarain, N., Gaffoor, Z., Martinson, F., Makanani, B., Pather, A., Naidoo, L., Husnik, M., Richardson, B.A., Parikh, U.M., Mellors, J.W., Marzinke, M.A., Hendrix, C.W., van der Straten, A., Ramjee, G., Chirenje, Z.M., Nakabiito, C., Taha, T.E., Jones, J., Mayo, A., Scheckter, R., Berthiaume, J., Livant, E., Jacobson, C., Ndase, P., White, R., Patterson, K., Germuga, D., Galaska, B., Bunge, K., Singh, D., Szydlo, D.W., Montgomery, E.T., Mensch, B.S., Torjesen, K., Grossman, C.I., Chakhtoura, N., Nel, A., Rosenberg, Z., McGowan, I., Hillier, S., Use of a vaginal ring containing Dapivirine for HIV-1 prevention in women. N. Engl. J. Med., 2016, 1–12.
63. Nel, A., Kapiga, S., Bekker, L., Borremans, D., Rosenberg, Z., For the IPM 027/The Ring Study Research Center Teams, Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women, in: Conf. Retroviruses Opportunistic Infect. p. Abstract 110LB http://www.croiconference.org/sessions/safety-and-efficacy-dapivirine-vaginal-ring-hiv-1-prevention-african-women, 2016.
64. Anukam, K.C., Osazuwa, E., Osemene, G.I., Ehigiagbe, F., Bruce, A.W., Reid, G., Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 8 (2006), 2772–2776.
65. Ya, W., Reifer, C., Miller, L.E., Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am. J. Obstet. Gynecol. 203 (2010), e1–6.
66. Mastromarino, P., Vitali, B., Mosca, L., Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol. 36 (2013), 229–238.
67. Barrons, R., Tassone, D., Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin. Ther. 30 (2008), 453–468.
68. Senok, A.C., Verstraelen, H., Temmerman, M., Botta, G.A., Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev., 2009, 10.1002/14651858.CD006289.pub2.
69. Marrazzo, J.M., Cook, R.L., Wiesenfeld, H.C., Murray, P.J., Busse, B., Krohn, M., Hillier, S.L., Women's satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis. J. Women's Health (Larchmt) 15 (2006), 1053–1060.
70. Stewart, M.L., Stewart, I., Vaginal applicator, USD320084 S. 1991.
71. Omar, R.F., Trottier, S., Brousseau, G., Ouellet, C., Danylo, A., Ong, T., Bergeron, M.G., Universal vaginal applicator for the uniform distribution of vaginal gel and cream formulations: a magnetic resonance imaging study. J. Obstet. Gynaecol. Can. 36 (2014), 42–50.
72. Omar, R.F., Trottier, S., Brousseau, G., Lamarre, A., Alexandre Gagnon, M.G., Bergeron, distribution of a vaginal gel (invisible condom®) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study. Contraception 77 (2008), 447–455.
73. Ahmad, F.J., Alam, M.A., Khan, Z.I., Khar, R.K., Ali, M., Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed vaginal infections. Acta Pharma. 58 (2008), 407–419.
74. Pedersen, C., Slepenkin, A., Andersson, S.B.E., Fagerberg, J.H., Bergström, C.A.S., Peterson, E.M., Formulation of the microbicide inp0341 for in vivo protection against a vaginal challenge by chlamydia trachomatis. PLoS One 9 (2014), 1–12.
75. Gupta, S., Kaur, I.P., Prabha, V., Evaluation of antifertility effect of gel formulation containing sperm immobilizing factor: in vitro and in vivo studies. Eur. J. Pharm. Sci. 81 (2016), 67–74.
76. Kiser, P.F., Mahalingam, A., Fabian, J., Smith, E., Damian, F.R., Peters, J.J., Katz, D.F., Elgendy, H., Clark, M.R., Friend, D.R., Design of tenofovir-UC781 combination microbicide vaginal gels. J. Pharm. Sci. 101 (2012), 1852–1864.
77. Chopra, S., Motwani, S.K., Iqbal, Z., Talegaonkar, S., Ahmad, F.J., Khar, R.K., Optimisation of polyherbal gels for vaginal drug delivery by box-Behnken statistical design. Eur. J. Pharm. Biopharm. 67 (2007), 120–131.
78. Bonferoni, M.C., Giunchedi, P., Scalia, S., Rossi, S., Sandri, G., Caramella, C., Chitosan gels for the vaginal delivery of lactic acid: relevance of formulation parameters to mucoadhesion and release mechanisms. AAPS PharmSciTech, 7, 2006, 104.
79. Senyiğit, Z.A., Karavana, S.Y., Eraç B., Gürsel, O., Limoncu, M.H., Baloğlu, E., Evaluation of chitosan based vaginal bioadhesive gel formulations for antifungal drugs. Acta Pharma. 64 (2014), 139–156.
80. Tuǧcu-Demiröz, F., Acartürk, F., Erdoǧan, D., Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations. Int. J. Pharm. 457 (2013), 25–39.
81. Svenson, S., Prud, R.K., Homme, Multifunctional Nanoparticles for Drug Delivery Applications: Imaging, Targeting, and Delivery. 2012, Springer, New York.
82. Navath, R.S., Menjoge, A.R., Dai, H., Romero, R., Kannan, S., Kannan, R.M., Injectable, P.A.M.A.M., Dendrimer-PEG hydrogels for the treatment of genital infections: formulation and in vitro and in vivo evaluation. Mol. Pharm. 8 (2011), 1209–1223.
83. Perioli, L., Ambrogi, V., Venezia, L., Pagano, C., Ricci, M., Rossi, C., Chitosan and a modified chitosan as agents to improve performances of mucoadhesive vaginal gels. Colloids Surf. B: Biointerfaces 66 (2008), 141–145.
84. Friedl, H.E., Dünnhaupt, S., Waldner, C., Bernkop-Schnürch, A., Preactivated thiomers for vaginal drug delivery vehicles. Biomaterials 34 (2013), 7811–7818.
85. Hassan, E.E., Gallo, J.M., A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm. Res. 7 (1990), 491–495.
86. Cevher, E., Sensoy, D., Taha, M.A.M., Araman, A., Effect of thiolated polymers to textural and mucoadhesive properties of vaginal gel formulations prepared with polycarbophil and chitosan. AAPS PharmSciTech 9 (2008), 953–965.
87. Aulton, Michael E., Aulton's Pharmaceutics. 2013.
88. Pavelić Ž., Škalko-Basnet, N., Schubert, R., Liposomal gels for vaginal drug delivery. Int. J. Pharm. 219 (2001), 139–149.
89. Pavelić Ž., Škalko-Basnet, N., Filipović-Grčić J., Martinac, A., Jalšenjak, I., Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J. Control. Release 106 (2005), 34–43.
90. Chen, D., Sun, K., Mu, H., Tang, M., Liang, R., Wang, A., Zhou, S., Sun, H., Zhao, F., Yao, J., Liu, W., pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system. Int. J. Nanomedicine 7 (2012), 2621–2630.
91. Chatterjee, A., Bhowmik, B.B., Thakur, Y.S., Formulation, in vitro and in vivo pharmacokinetics of anti-hiv vaginal bioadhesive gel. J. Young Pharm. 3 (2011), 83–89.
92. Chatterjee, A., Kumar, L., Bhowmik, B.B., Gupta, A., Microparticulated anti-HIV vaginal gel: in vitro-in vivo drug release and vaginal irritation study. Pharm. Dev. Technol. 16 (2011), 466–473.
93. Frank, L.A., Sandri, G., D'Autilia, F., Contri, R.V., Bonferoni, M.C., Caramella, C., Frank, A.G., Pohlmann, A.R., Guterres, S.S., Chitosan gel containing polymeric nanocapsules: a new formulation for vaginal drug delivery. Int. J. Nanomedicine 9 (2014), 3151–3161.
94. Baloglu, E., Karavana, S.Y., Senyigit, Z.A., Hilmioglu-Polat, S., Metin, D.Y., Zekioglu, O., Guneri, T., Jones, D.S., In-situ gel formulations of econazole nitrate: preparation and in-vitro and in-vivo evaluation. J. Pharm. Pharmacol. 63 (2011), 1274–1282.
95. el Ibrahim, S.A., Ismail, S., Fetih, G., Shaaban, O., Hassanein, K., Abdellah, N.H., Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations for vaginal application. Acta Pharma. 62 (2012), 59–70.
96. Aka-Any-Grah, A., Bouchemal, K., Koffi, A., Agnely, F., Zhang, M., Djabourov, M., Ponchel, G., Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur. J. Pharm. Biopharm. 76 (2010), 296–303.
97. Yun Chang, J., Oh, Y.K., Soo Kong, H., Jung Kim, E., Deuk Jang, D., Taek Nam, K., Kim, C.K., Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels on vaginitis. J. Control. Release 82 (2002), 39–50.
98. de Araújo Pereira, R.R., Ribeiro Godoy, J.S., Stivalet Svidzinski, T.I., Bruschi, M.L., Preparation and characterization of mucoadhesive thermoresponsive systems containing propolis for the treatment of vulvovaginal candidiasis. J. Pharm. Sci. 102 (2013), 1222–1234.
99. Andrews, G.P., Donnelly, L., Jones, D.S., Curran, R.M., Morrow, R.J., Woolfson, A.D., Malcolm, R.K., Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery. Biomacromolecules 10 (2009), 2427–2435.
100. Curran, R.M., Donnelly, L., Morrow, R.J., Fraser, C., Andrews, G., Cranage, M., Malcolm, R.K., Shattock, R.J., Woolfson, A.D., Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 27 (2009), 6791–6798.
101. Kim, Y.T., Shin, B.K., Garripelli, V.K., Kim, J.K., Davaa, E., Jo, S., Park, J.S., A thermosensitive vaginal gel formulation with HP??CD for the pH-dependent release and solubilization of amphotericin B. Eur. J. Pharm. Sci. 41 (2010), 399–406.
102. Bilensoy, E., Rouf, M.A., Vural, I., Hincal, A.A., Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to beta-cyclodextrin. J. Control. Release 116 (2006), e107–e109.
103. Liu, Y., Ying Zhu, Y., Wei, G., Yue Lu, W., Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved in vitro and in vivo sustained-release properties. Eur. J. Pharm. Sci. 37 (2009), 306–312.
104. Almomen, A., Cho, S., Yang, C.H., Li, Z., Jarboe, E.A., Peterson, C.M., Huh, K.M., Janát-Amsbury, M.M., Thermosensitive progesterone hydrogel: a safe and effective new formulation for vaginal application. Pharm. Res., 2015, 2266–2279.
105. Mehendale, S., Deshpande, S., Kohli, R., Tsui, S., Tolley, E., Acceptability of coitally-associated versus daily use of 1% tenofovir vaginal gel among women in Pune, India. Int. Health. 4 (2012), 63–69.
106. Mahan, E.D., Zaveri, T., Ziegler, G.R., Hayes, J.E., Relationships between perceptual attributes and rheology in over-the-counter vaginal products: a potential tool for microbicide development. PLoS One, 9, 2014, e105614.
107. Morrow, K.M., Rosen, R.K., Fava, J.L., Rohan, L.C., Kojic, E.M., Friend, D.R., Katz, D.F., Buckheit, R.W., “He said, she said.” exploring couples’ sensory perceptions and experiences with vaginal gels & film: implications for microbicide development. AIDS Res. Hum. Retrovir. 30 (2014), A86–A87.
108. Morrow, K.M., Rosen, R.K., Vargas, S.E., Katz, D.F., Fava, J.L., Kojic, E.M., Friend, D.R., Rohan, L.C., Ham, A.S., Buckheit, R.W., More.? less.? just right.? the role of perceived volume in gel and film perceptibility during intercourse, and its impact on product preference. AIDS Res. Hum. Retrovir., 30, 2014, A145.
109. Van Den Berg, J.J., Rosen, R.K., Bregman, D.E., Thompson, L.A., Jensen, K.M., Kiser, P.F., Katz, D.F., Buckheit, K., Buckheit, R.W., Morrow, K.M., Set it and forget it: Women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav. 18 (2014), 862–870.
110. FDA, Guidance for Industry Vaginal Microbicides: Development for the Prevention of HIV Infection Guidance for Industry Vaginal Microbicides: Development for the Prevention of HIV Infection. 2014.
111. FDA, Vulvovaginal Candidiasis: Developing Drugs for Treatment Guidance for Industry Vulvovaginal Candidiasis: Developing Drugs for Treatment Guidance for Industry. 2016.
112. FDA, Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry. 2016.
113. FDA, Guidance for Industry Noncontraceptive Estrogen Drug Guidance for Industry Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms — Recommended Prescribing Information for Health Care Provid. 2005.
114. FDA, Guidance for Industry Guidance for Industry Estrogen and Estrogen/Progestin Drug. 2003.
115. FDA, Guidance for the Development of Vaginal Contraceptive Drugs. 1997.
116. EMA Committee for Medicinal Products for Human use, Concept Paper on the Development of a Guideline on Quality and Equivalence of Topical Products, EMA/CHMP/Q. 2014.
117. FDA, Guidance for Industry Residual Drug in Transdermal and Related Drug Delivery Systems Guidance for Industry Residual Drug in Transdermal and Related Drug Delivery. 2011.
118. FDA, Guidance for Industry Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. 2005.
119. FDA, Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. 2010.
120. FDA, Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm125951.htm, 2005 (accessed June 2, 2017).
121. MerckSerono, Crinone® 8% w/w Vaginal Gel - SPC. 2001.
122. Hurst, B., Jones, A., Elliot, M., Marchburn, P., Matthews, M., Absorption of vaginal estrogen cream during sexual intercourse: a prospective, randomized, controlled trial. J. Reprod. Med. 53 (2008), 29–32.
123. Merriam, K.S., Leake, K.A., Elliot, M., Matthews, M.L., Usadi, R.S., Hurst, B.S., Sexual absorption of vaginal progesterone: a randomized control trial. Int. J. Endocrinol., 2015, 2015, 10.1155/2015/685281 (online only, ID 685281).
124. Brache, V., Croxatto, H., Kumar, N., Sitruk-Ware, R., Cochon, L., Schiappacasse, V., Sivin, I., Munoz, C., Maguire, R., Faundes, A., Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard® gel: a randomized, cross-over, pharmacokinetic study. Contraception 79 (2009), 150–154.
125. Zargooshi, J., Kavoussi, H., Rahmanian, E., Motaee, H., Kohzadi, M., Nourizad, S., Postcoital penile drug eruption in a co-Trimoxazole-sensitive patient following vaginal use of triple sulfa vaginal cream by his partner. J. Sex. Med. 9 (2012), 758–760.
126. Einer-Jensen, N., Hunter, R.H.F., Counter-current transfer in reproductive biology. Reproduction 129 (2005), 9–18.
127. Malcolm, R.K., Lowry, D., Boyd, P., Geer, L., Veazey, R.S., Goldman, L., Klasse, P.J., Shattock, R.J., Moore, J.P., Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. J. Antimicrob. Chemother. 69 (2014), 1325–1329.
128. Borin, M.T., Systemic absorption of clindamycin following intra vaginal application of clindamycin phosphate 1% cream. J. Clin. Pharmacol. 30 (1990), 33–38.
129. Houang, E.T., Lawrence, A.G., Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300-mg tioconazole ovule. Antimicrob. Agents Chemother. 27 (1985), 964–965.
130. King, C.T., Rogers, P.D., Cleary, J.D., Chapman, S.W., Antifungal therapy during pregnancy. Clin. Infect. Dis. 27 (1998), 1151–1160.
131. Edwards, D., Panay, N., Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?. Climacteric 19 (2016), 151–161.
132. Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiègne-Traoré V., Uaheowitchai, C., Abdool Karim, S.S., Mâsse, B., Perriëns, J., Laga, M., Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360 (2002), 971–977.
133. Fichorova, R.N., Tucker, L.D., Anderson, D.J., The molecular basis of Nonoxynol-9–induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 184 (2001), 418–428.
134. Abdool, K.Q., Abdool Karim, S.S., Frohlich, J.A., Grobler, A.C., Baxter, C., Mansoor, L.E., Kharsany, A.B., Sibeko, S., Mlisana, K.P., Omar, Z., Gengiah, T.N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., Taylor, D., T. Group, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 80 (2010), 1168–1174.
135. Abdool Karim, S.S., Richardson, B.A., Ramjee, G., Hoffman, I.F., Chirenje, Z.M., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., Moench, T.R., Piwowar-Manning, E., Mâsse, B., Hillier, S.L., Soto-Torres, L. et al., AIDS 25 (2011), 957–966.
136. Joglekar, N., Joshi, S., Kakde, M., Fang, G., Cianciola, M., Reynolds, S., Mehendale, S., The HIV prevention trial network, Acceptability of PRO2000 Vaginal Gel among HIV un-infected Women in Pune, India, AIDS Care. vol. 19, 2007, 817–821.
137. Gengiah, T.N., Moosa, A., Naidoo, A., Mansoor, L.E., Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int. J. Clin. Pharm. 36 (2014), 70–85.
138. Peterson, L., Nanda, K., Opoku, B.K., Ampofo, W.K., Owusu-Amoaka, M., Boakye, A.Y., Rountree, W., Troxler, A., Dominik, R., Roddy, R., Dorflinger, L., SAVVY® (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One, 2, 2007, 10.1371/journal.pone.0001312.
139. Feldblum, P.J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M.O., Wang, L., Nanda, K., Roundtree, W., SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One, 3, 2008, 10.1371/journal.pone.0001474.
140. Starpharma, VivaGel availability. http://www.starpharma.com/vivagel/vivagel_availability (accessed June 5, 2017).
141. Moscicki, A.-B., Kaul, R., Yifei, M., Scott, M.E., Daud, I.I., Bukusi, E.A., Shiboski, S., Rebbapragada, A., Huibner, S., Cohen, C.R., Author, C., Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% SPL 7013 gel (VivaGel ®) to assess expanded safety. J Acquir Immune Defic Syndr J Acquir Immune Defic Syndr. Febr. 1 (2012), 134–140.
142. Cohen, C.R., Brown, J., Moscicki, A.B., Bukusi, E.A., Paull, J.R.A., Price, C.F., Shiboski, S., A phase I randomized placebo controlled trial of the safety of 3% SPL7013 gel (VivaGel??) in healthy young women administered twice daily for 14 days. PLoS One, 6, 2011.
143. Shaaban, O.M., Fetih, G.N., Abdellah, N.H., Ismail, S., Ibrahim, M.A., Ibrahim, E.S.A., Pilot randomized trial for treatment of bacterial vaginosis using in situ forming metronidazole vaginal gel. J. Obstet. Gynaecol. Res. 37 (2011), 874–881.
144. Rapkin, R.B., Achilles, S.L., Schwarz, E.B., Meyn, L., Cremer, M., Boraas, C.M., Chen, B.A., Self-administered lidocaine gel for intrauterine device insertion in nulliparous women. Obstet. Gynecol. 128 (2016), 621–628.
145. O'Brien, J.M., Defranco, E.A., Adair, C.D., Lewis, D.F., Hall, D.R., How, H., Bsharat, M., Creasy, G.W., Progesterone Vaginal Gel Study, Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 34 (2009), 653–659.